The Annual Blood-Brain Barrier Consortium Meeting

描述（由申请人提供）：第17届血脑屏障（BBB）联盟年会定于2011年3月17日至19日在华盛顿史蒂文森的Skamania Lodge举行。年会的总体目标是促进研究血脑屏障和中枢神经系统（CNS）的科学家和临床医生之间的互动，并帮助将基础和临床前研究进展转化为神经肿瘤学和神经病学的临床试验。每次会议都会聚焦一两个研究领域，这些领域的进展可能会影响脑输送、脑成像或脑肿瘤治疗。2011年会议的具体目标是：癌症治疗对认知和生活质量的影响。我们将讨论放疗、化疗和联合治疗方式对恶性脑肿瘤和系统性癌症患者认知和生活质量的影响，以及消除治疗不良反应的新方法。具体目标2。大脑是免疫和药理学上的特权部位，中枢神经系统疾病是血脑屏障破坏的表现。主要焦点将是炎症在脑肿瘤、多发性硬化症、阿尔茨海默病和帕金森病、脑血管疾病和中枢神经系统遗传疾病中的作用。具体目标3。推进BBB联盟的临床研究，包括当前临床试验的更新，新的临床研究方案的开发，以及将研究从实验室带到临床的转化方案的规划。会议将强调世界知名专家的主题演讲和简短的讲台演讲，然后是大型小组讨论，以及小组讨论和海报会议。在未来几年的会议中，我们计划继续讨论脑血管生物学、肿瘤成像和治疗以及血脑屏障生理学领域的基础科学、临床前和临床研究的当前问题、最新进展和未来方向。向科学界传播会议结果是BBB会议的一个主要目标。在之前的资助期内，我们发表了五篇会议报告/综述文章，《自然评论神经科学》正在审查2009年BBB会议的摘要报告，2010年3月会议的报告正在进行中。BBB联盟会议的目标人群包括学术界、工业界和NIH的临床医生以及BBB和神经肿瘤学研究项目的研究人员，特别强调转化研究。我们积极招募并鼓励年轻、少数族裔和女性临床医生和科学家的参与。自从上次更新以来，我们增加了我们的尝试，包括新的BBB研究人员，年轻的研究人员，博士后和研究生，少数民族科学家，以及残疾科学家，特别是那些有听力障碍的科学家。本次年度BBB会议将继续为转化BBB和中枢神经系统研究以及开发新的临床试验提供论坛，以改善脑肿瘤和中枢神经系统疾病的预后。

DESCRIPTION (provided by applicant): The seventeenth Annual Blood-Brain Barrier (BBB) Consortium Meeting is scheduled for March 17-19, 2011, at Skamania Lodge in Stevenson, Washington. The overall objectives of the annual meeting are to facilitate interactions between scientists and clinicians studying the BBB and the central nervous system (CNS), and to help translate basic and preclinical research advances into clinical trials in neuro-oncology and neurology. Every meeting spotlights one or two research areas in which advances may impact brain delivery, brain imaging, or brain tumor therapy. The specific aims of the 2011 meeting are: Specific Aim 1. The impact of cancer therapies on cognition and quality of life. We will discuss treatment effects of radiotherapy, chemotherapy and combined modality approaches on cognition and quality of life, in patients with malignant brain tumors and systemic cancers as well, and new approaches to abrogate the adverse effects of treatment. Specific Aim 2. The brain as an immunologically and pharmacologically privileged site, and CNS disease as a manifestation of BBB breakdown. The major foci will be the role of inflammation in brain tumors, multiple sclerosis, Alzheimer's and Parkinson's disease, cerebrovascular disease and CNS genetic disease. Specific Aim 3. Advancing BBB Consortium clinical research, including updates on current clinical trials, development of new clinical research protocols, and planning of translational protocols to bring research from the lab to the clinic. The meeting will emphasize keynote presentations and brief podium presentations by world-renowned experts followed by large group discussions, as well as panel discussions and poster sessions. In future years of this ongoing meeting we plan to continue to discuss current issues, recent advances and future directions in basic science, preclinical, and clinical research in the fields of cerebrovascular biology, tumor imaging and therapy, and BBB physiology. Dissemination of meeting findings to the scientific community is a major goal of the BBB meeting. During the previous funding period we published five meeting report/review articles, a summary report of the 2009 BBB meeting is under review at Nature Reviews Neuroscience, and a report from the March 2010 meeting is underway. The target population for the BBB Consortium meeting includes academic, industry, and NIH clinicians and researchers with research programs in the BBB and neuro- oncology, with a particular emphasis on translational research. We actively recruit and encourage the participation of young, minority, and women clinicians and scientists. Since the last renewal we have increased our attempts to include new BBB researchers, young investigators, post doctoral and graduate students, minority scientists, as well as disabled scientists, particularly those with hearing impairment. This annual BBB meeting will continue to provide a forum for translational BBB and CNS research and the development of new clinical trials to improve outcomes in brain tumors and CNS disease.